| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Calculi | 160 | 2023 | 341 | 17.460 |
Why?
|
| Calcium Oxalate | 100 | 2023 | 186 | 8.330 |
Why?
|
| Calcium | 104 | 2023 | 1172 | 5.350 |
Why?
|
| Hypercalciuria | 15 | 2023 | 47 | 3.640 |
Why?
|
| Kidney | 44 | 2023 | 1145 | 3.560 |
Why?
|
| Calcium Phosphates | 32 | 2020 | 77 | 3.450 |
Why?
|
| Urine | 20 | 2019 | 89 | 2.370 |
Why?
|
| Acid-Base Equilibrium | 6 | 2021 | 33 | 2.110 |
Why?
|
| Kidney Medulla | 21 | 2023 | 81 | 2.010 |
Why?
|
| Urinary Calculi | 17 | 2009 | 46 | 1.950 |
Why?
|
| Uric Acid | 41 | 2020 | 136 | 1.850 |
Why?
|
| Kidney Tubules, Proximal | 9 | 2019 | 60 | 1.830 |
Why?
|
| Oxalates | 20 | 2022 | 48 | 1.650 |
Why?
|
| Crystallization | 45 | 2019 | 210 | 1.530 |
Why?
|
| Kidney Tubules | 15 | 2020 | 92 | 1.450 |
Why?
|
| Kidney Failure, Chronic | 12 | 2019 | 413 | 1.450 |
Why?
|
| Hydrogen-Ion Concentration | 34 | 2020 | 499 | 1.260 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 219 | 1.190 |
Why?
|
| Nephrolithiasis | 5 | 2016 | 23 | 1.180 |
Why?
|
| Humans | 234 | 2023 | 89063 | 1.140 |
Why?
|
| Hyperoxaluria | 8 | 2022 | 26 | 1.110 |
Why?
|
| Parathyroid Hormone | 26 | 2023 | 216 | 1.100 |
Why?
|
| Glycoproteins | 19 | 1994 | 234 | 1.100 |
Why?
|
| Cystinuria | 8 | 2010 | 13 | 1.090 |
Why?
|
| Male | 154 | 2021 | 42251 | 1.080 |
Why?
|
| Calcium, Dietary | 21 | 2023 | 64 | 1.010 |
Why?
|
| Phosphorus | 21 | 2015 | 117 | 0.950 |
Why?
|
| Female | 141 | 2021 | 46011 | 0.940 |
Why?
|
| Middle Aged | 84 | 2021 | 25863 | 0.930 |
Why?
|
| Glomerular Filtration Rate | 12 | 2019 | 275 | 0.900 |
Why?
|
| Vitamin D Deficiency | 2 | 2022 | 103 | 0.880 |
Why?
|
| Calcitriol | 25 | 2008 | 173 | 0.870 |
Why?
|
| Renal Dialysis | 6 | 2019 | 335 | 0.860 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2016 | 71 | 0.860 |
Why?
|
| Creatinine | 18 | 2021 | 293 | 0.860 |
Why?
|
| Sulfates | 2 | 2021 | 57 | 0.810 |
Why?
|
| Adult | 84 | 2021 | 26507 | 0.800 |
Why?
|
| Vitamin D | 9 | 2022 | 268 | 0.770 |
Why?
|
| Diuretics | 15 | 2013 | 75 | 0.740 |
Why?
|
| Diet | 18 | 2019 | 442 | 0.730 |
Why?
|
| Aging | 4 | 2021 | 716 | 0.720 |
Why?
|
| Acid-Base Imbalance | 1 | 2019 | 4 | 0.700 |
Why?
|
| Cystine | 5 | 2010 | 15 | 0.660 |
Why?
|
| Postprandial Period | 5 | 2017 | 47 | 0.650 |
Why?
|
| Veins | 1 | 2019 | 95 | 0.640 |
Why?
|
| Brachiocephalic Veins | 2 | 2009 | 34 | 0.620 |
Why?
|
| Risk Factors | 24 | 2020 | 5466 | 0.610 |
Why?
|
| Hyperparathyroidism, Secondary | 5 | 2015 | 68 | 0.610 |
Why?
|
| Health Status Disparities | 1 | 2020 | 187 | 0.610 |
Why?
|
| Uromodulin | 10 | 2023 | 15 | 0.590 |
Why?
|
| Thiazides | 3 | 2022 | 16 | 0.590 |
Why?
|
| Chlorthalidone | 4 | 2013 | 18 | 0.590 |
Why?
|
| Parathyroid Glands | 6 | 2013 | 74 | 0.580 |
Why?
|
| Sex Factors | 17 | 2019 | 1063 | 0.570 |
Why?
|
| Citric Acid | 8 | 2021 | 38 | 0.560 |
Why?
|
| Phosphates | 18 | 2018 | 160 | 0.560 |
Why?
|
| Apatites | 9 | 2017 | 19 | 0.550 |
Why?
|
| Biomarkers | 9 | 2020 | 1755 | 0.550 |
Why?
|
| Brachiocephalic Trunk | 1 | 2016 | 14 | 0.550 |
Why?
|
| Medullary Sponge Kidney | 3 | 2015 | 6 | 0.540 |
Why?
|
| Citrates | 9 | 2017 | 28 | 0.540 |
Why?
|
| Hyperparathyroidism | 14 | 2008 | 67 | 0.520 |
Why?
|
| Poetry as Topic | 2 | 2011 | 5 | 0.520 |
Why?
|
| Medicine in Literature | 2 | 2011 | 8 | 0.520 |
Why?
|
| Specimen Handling | 3 | 2002 | 102 | 0.520 |
Why?
|
| Proteinuria | 4 | 2019 | 67 | 0.520 |
Why?
|
| Sodium-Hydrogen Exchangers | 2 | 2018 | 77 | 0.520 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 198 | 0.520 |
Why?
|
| Aged | 40 | 2020 | 19077 | 0.500 |
Why?
|
| Durapatite | 2 | 2014 | 28 | 0.500 |
Why?
|
| Hypercalcemia | 8 | 2008 | 60 | 0.490 |
Why?
|
| Rats | 33 | 2010 | 4040 | 0.490 |
Why?
|
| Receptors, Calcium-Sensing | 3 | 2023 | 14 | 0.480 |
Why?
|
| Sodium | 17 | 2022 | 331 | 0.480 |
Why?
|
| Phosphoproteins | 2 | 2018 | 261 | 0.480 |
Why?
|
| Kidney Diseases | 10 | 2014 | 319 | 0.480 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 13 | 2011 | 37 | 0.470 |
Why?
|
| Loop of Henle | 6 | 2018 | 11 | 0.460 |
Why?
|
| Biopsy | 10 | 2020 | 1182 | 0.460 |
Why?
|
| Receptors, Calcitriol | 2 | 2004 | 130 | 0.450 |
Why?
|
| Mucoproteins | 8 | 1998 | 14 | 0.450 |
Why?
|
| Monocytes | 2 | 2004 | 218 | 0.440 |
Why?
|
| Intestinal Absorption | 13 | 2008 | 124 | 0.440 |
Why?
|
| Acidosis | 10 | 1986 | 55 | 0.440 |
Why?
|
| Osteogenesis | 1 | 2015 | 255 | 0.440 |
Why?
|
| Calcium Metabolism Disorders | 9 | 1994 | 14 | 0.430 |
Why?
|
| Endoscopy | 6 | 2016 | 348 | 0.420 |
Why?
|
| Bone and Bones | 6 | 2006 | 269 | 0.410 |
Why?
|
| Osteopontin | 4 | 2010 | 47 | 0.400 |
Why?
|
| Algorithms | 2 | 2019 | 1875 | 0.400 |
Why?
|
| Nephrostomy, Percutaneous | 7 | 2015 | 32 | 0.390 |
Why?
|
| Jejunoileal Bypass | 3 | 2008 | 6 | 0.380 |
Why?
|
| Ureteroscopy | 4 | 2022 | 38 | 0.380 |
Why?
|
| Animals | 57 | 2015 | 27317 | 0.380 |
Why?
|
| Intestine, Small | 4 | 2010 | 299 | 0.380 |
Why?
|
| Magnesium | 14 | 2023 | 178 | 0.360 |
Why?
|
| Benzothiadiazines | 10 | 1999 | 13 | 0.360 |
Why?
|
| Allopurinol | 16 | 2010 | 77 | 0.350 |
Why?
|
| Time Factors | 18 | 2017 | 5320 | 0.340 |
Why?
|
| Attitude to Health | 1 | 2011 | 222 | 0.340 |
Why?
|
| Secondary Prevention | 4 | 2016 | 158 | 0.330 |
Why?
|
| Bone Density | 3 | 2006 | 209 | 0.320 |
Why?
|
| Obesity | 4 | 2010 | 966 | 0.320 |
Why?
|
| X-Ray Microtomography | 4 | 2022 | 89 | 0.320 |
Why?
|
| Recurrence | 19 | 2016 | 1140 | 0.310 |
Why?
|
| Renal Elimination | 2 | 2020 | 8 | 0.310 |
Why?
|
| Diuresis | 4 | 2003 | 26 | 0.310 |
Why?
|
| Bariatric Surgery | 2 | 2008 | 195 | 0.300 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 2362 | 0.300 |
Why?
|
| Case-Control Studies | 8 | 2021 | 1855 | 0.300 |
Why?
|
| Fistula | 1 | 2008 | 42 | 0.300 |
Why?
|
| Kidney Tubules, Collecting | 5 | 2020 | 24 | 0.290 |
Why?
|
| Renal Reabsorption | 2 | 2018 | 7 | 0.290 |
Why?
|
| Nephrocalcinosis | 3 | 2015 | 9 | 0.290 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 217 | 0.290 |
Why?
|
| Nephrectomy | 8 | 2006 | 293 | 0.290 |
Why?
|
| Lithotripsy | 5 | 2016 | 42 | 0.280 |
Why?
|
| Stress, Mechanical | 2 | 2019 | 253 | 0.280 |
Why?
|
| Bone Resorption | 1 | 2006 | 42 | 0.280 |
Why?
|
| Young Adult | 9 | 2019 | 6288 | 0.280 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 497 | 0.270 |
Why?
|
| Magnesium Compounds | 4 | 2008 | 7 | 0.270 |
Why?
|
| Potassium | 11 | 2021 | 253 | 0.270 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2010 | 42 | 0.260 |
Why?
|
| Tiopronin | 3 | 2006 | 6 | 0.260 |
Why?
|
| Microscopy, Electron, Transmission | 5 | 2014 | 136 | 0.260 |
Why?
|
| Penicillamine | 3 | 2001 | 12 | 0.250 |
Why?
|
| Kidney Cortex | 4 | 2010 | 34 | 0.240 |
Why?
|
| Cholecalciferol | 1 | 2004 | 35 | 0.240 |
Why?
|
| Captopril | 2 | 2001 | 20 | 0.240 |
Why?
|
| Carbon Dioxide | 8 | 2017 | 202 | 0.240 |
Why?
|
| Anions | 2 | 2021 | 31 | 0.230 |
Why?
|
| Water-Electrolyte Balance | 3 | 2020 | 67 | 0.230 |
Why?
|
| Cohort Studies | 7 | 2018 | 2863 | 0.230 |
Why?
|
| Solubility | 5 | 2010 | 179 | 0.230 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 293 | 0.220 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 8 | 0.220 |
Why?
|
| Down-Regulation | 1 | 2004 | 519 | 0.210 |
Why?
|
| Nephrons | 3 | 2008 | 17 | 0.210 |
Why?
|
| Follow-Up Studies | 9 | 2012 | 3657 | 0.210 |
Why?
|
| Fasting | 3 | 2015 | 163 | 0.210 |
Why?
|
| Urodynamics | 2 | 2020 | 122 | 0.200 |
Why?
|
| Vitamins | 1 | 2022 | 83 | 0.200 |
Why?
|
| Kidney Function Tests | 3 | 2015 | 113 | 0.200 |
Why?
|
| Local Area Networks | 1 | 2001 | 1 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2022 | 8203 | 0.190 |
Why?
|
| Acidosis, Renal Tubular | 6 | 2010 | 11 | 0.190 |
Why?
|
| Hypertension | 6 | 2005 | 741 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2006 | 1237 | 0.180 |
Why?
|
| Basement Membrane | 3 | 2018 | 55 | 0.180 |
Why?
|
| Struvite | 4 | 2008 | 7 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2001 | 230 | 0.180 |
Why?
|
| Gastrointestinal Absorption | 1 | 2019 | 3 | 0.180 |
Why?
|
| Ammonium Compounds | 1 | 2019 | 8 | 0.180 |
Why?
|
| Colorimetry | 1 | 1999 | 8 | 0.180 |
Why?
|
| Ileostomy | 2 | 2010 | 29 | 0.170 |
Why?
|
| Colon | 5 | 1984 | 509 | 0.170 |
Why?
|
| Losartan | 1 | 1999 | 30 | 0.170 |
Why?
|
| Albuminuria | 1 | 2019 | 48 | 0.170 |
Why?
|
| Patient-Specific Modeling | 1 | 2019 | 20 | 0.170 |
Why?
|
| Beverages | 1 | 1999 | 17 | 0.170 |
Why?
|
| Kidney Tubules, Distal | 3 | 2015 | 19 | 0.160 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1998 | 7 | 0.160 |
Why?
|
| Foscarnet | 1 | 1998 | 12 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 337 | 0.160 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 1998 | 15 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 33 | 0.160 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2018 | 13 | 0.160 |
Why?
|
| Hypophosphatemia | 1 | 2018 | 7 | 0.160 |
Why?
|
| Sodium-Hydrogen Exchanger 3 | 1 | 2018 | 32 | 0.160 |
Why?
|
| PDZ Domains | 1 | 2018 | 14 | 0.160 |
Why?
|
| Antihypertensive Agents | 2 | 1999 | 249 | 0.160 |
Why?
|
| Organic Anion Transporters | 1 | 2018 | 26 | 0.160 |
Why?
|
| Adolescent | 17 | 2019 | 9237 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2009 | 87 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 1998 | 121 | 0.150 |
Why?
|
| Trichlormethiazide | 7 | 1988 | 9 | 0.150 |
Why?
|
| Calculi | 2 | 2010 | 5 | 0.150 |
Why?
|
| Alpha-Globulins | 2 | 2007 | 11 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 145 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2020 | 2290 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2020 | 9003 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2016 | 4273 | 0.140 |
Why?
|
| Urinalysis | 1 | 2016 | 31 | 0.140 |
Why?
|
| Bicarbonates | 8 | 2019 | 58 | 0.140 |
Why?
|
| Quaternary Ammonium Compounds | 4 | 2006 | 80 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2003 | 575 | 0.140 |
Why?
|
| Pregnancy Complications | 5 | 1989 | 345 | 0.140 |
Why?
|
| Prognosis | 5 | 2015 | 3773 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 432 | 0.130 |
Why?
|
| Ammonium Chloride | 5 | 2015 | 21 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2015 | 1706 | 0.130 |
Why?
|
| Chicago | 1 | 2020 | 1423 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2019 | 729 | 0.130 |
Why?
|
| Kidney Transplantation | 3 | 2009 | 849 | 0.130 |
Why?
|
| Nephrolithotomy, Percutaneous | 3 | 2020 | 8 | 0.130 |
Why?
|
| Nephrology | 1 | 2015 | 41 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 1998 | 475 | 0.120 |
Why?
|
| Hydroxyproline | 2 | 2006 | 11 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 105 | 0.120 |
Why?
|
| Reference Values | 5 | 1999 | 661 | 0.120 |
Why?
|
| Duodenum | 2 | 1986 | 103 | 0.120 |
Why?
|
| Serum Albumin | 2 | 1999 | 127 | 0.120 |
Why?
|
| Rats, Inbred Strains | 8 | 1986 | 312 | 0.120 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2013 | 4 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 229 | 0.110 |
Why?
|
| Age Factors | 6 | 2012 | 1867 | 0.110 |
Why?
|
| Lithium | 2 | 2010 | 59 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 4 | 2015 | 1043 | 0.110 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 8 | 0.110 |
Why?
|
| Amino Acids | 9 | 1991 | 245 | 0.110 |
Why?
|
| Linear Models | 4 | 2021 | 421 | 0.110 |
Why?
|
| United States | 6 | 2015 | 6955 | 0.110 |
Why?
|
| Mannitol | 5 | 1986 | 50 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 121 | 0.110 |
Why?
|
| Fluid Therapy | 2 | 2011 | 51 | 0.100 |
Why?
|
| Purines | 6 | 1994 | 93 | 0.100 |
Why?
|
| Intestinal Mucosa | 4 | 1984 | 805 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 2657 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2015 | 351 | 0.100 |
Why?
|
| Milk | 1 | 1992 | 53 | 0.100 |
Why?
|
| Diet, Protein-Restricted | 1 | 2011 | 3 | 0.100 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2011 | 6 | 0.100 |
Why?
|
| Kinetics | 9 | 1991 | 1528 | 0.100 |
Why?
|
| Siblings | 1 | 2012 | 111 | 0.100 |
Why?
|
| Fruit | 1 | 1992 | 76 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2752 | 0.100 |
Why?
|
| Observer Variation | 3 | 2019 | 610 | 0.100 |
Why?
|
| Osmolar Concentration | 5 | 2007 | 181 | 0.100 |
Why?
|
| Mice | 6 | 2010 | 11737 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6777 | 0.090 |
Why?
|
| Kidney Concentrating Ability | 1 | 1990 | 9 | 0.090 |
Why?
|
| Hyaluronic Acid | 2 | 2008 | 49 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2019 | 771 | 0.090 |
Why?
|
| Ileum | 3 | 2005 | 160 | 0.090 |
Why?
|
| Drug Design | 1 | 2010 | 125 | 0.090 |
Why?
|
| Ions | 3 | 2002 | 75 | 0.090 |
Why?
|
| Vertebrates | 1 | 1991 | 103 | 0.090 |
Why?
|
| Acute Disease | 3 | 2008 | 841 | 0.090 |
Why?
|
| Hemodialysis, Home | 1 | 2009 | 1 | 0.090 |
Why?
|
| Dialysis Solutions | 1 | 2009 | 7 | 0.090 |
Why?
|
| Menopause | 2 | 1989 | 76 | 0.090 |
Why?
|
| beta 2-Microglobulin | 1 | 2009 | 24 | 0.090 |
Why?
|
| Abdomen | 1 | 2010 | 122 | 0.090 |
Why?
|
| Risk | 6 | 2005 | 657 | 0.090 |
Why?
|
| 1-Carboxyglutamic Acid | 2 | 1987 | 2 | 0.080 |
Why?
|
| Child | 13 | 2019 | 7149 | 0.080 |
Why?
|
| Femur Neck | 2 | 2006 | 41 | 0.080 |
Why?
|
| Models, Biological | 5 | 2015 | 1763 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1989 | 18 | 0.080 |
Why?
|
| Intestines | 2 | 2010 | 416 | 0.080 |
Why?
|
| Homeostasis | 3 | 1986 | 413 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1989 | 45 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 60 | 0.080 |
Why?
|
| Pregnancy Proteins | 1 | 1988 | 38 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 126 | 0.080 |
Why?
|
| Spine | 2 | 2006 | 102 | 0.080 |
Why?
|
| Donor Selection | 1 | 2009 | 74 | 0.080 |
Why?
|
| Insulin | 1 | 2013 | 1146 | 0.080 |
Why?
|
| Proteins | 3 | 2006 | 786 | 0.080 |
Why?
|
| Phlebography | 1 | 2008 | 66 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 1989 | 118 | 0.080 |
Why?
|
| Urologists | 2 | 2019 | 29 | 0.080 |
Why?
|
| Alkalies | 2 | 2022 | 8 | 0.070 |
Why?
|
| Furosemide | 2 | 1986 | 34 | 0.070 |
Why?
|
| Pregnancy | 7 | 1989 | 3009 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1992 | 435 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1715 | 0.070 |
Why?
|
| Health Surveys | 2 | 2005 | 240 | 0.070 |
Why?
|
| Outpatients | 1 | 2008 | 100 | 0.070 |
Why?
|
| Kidney Calices | 1 | 2007 | 5 | 0.070 |
Why?
|
| Iothalamic Acid | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cell Line | 2 | 2004 | 2495 | 0.070 |
Why?
|
| Culture Media | 4 | 1989 | 147 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 1796 | 0.070 |
Why?
|
| Chemistry | 2 | 2001 | 54 | 0.070 |
Why?
|
| Dietary Proteins | 1 | 2007 | 30 | 0.070 |
Why?
|
| Chemical Phenomena | 2 | 2001 | 72 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 269 | 0.070 |
Why?
|
| Microvilli | 1 | 2006 | 43 | 0.070 |
Why?
|
| Biological Assay | 2 | 2006 | 79 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2003 | 333 | 0.070 |
Why?
|
| X-Ray Diffraction | 3 | 2003 | 126 | 0.070 |
Why?
|
| Diverticulum | 1 | 2007 | 45 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2006 | 132 | 0.070 |
Why?
|
| Prothrombin | 1 | 2006 | 17 | 0.070 |
Why?
|
| CD59 Antigens | 1 | 2006 | 17 | 0.070 |
Why?
|
| Calgranulin B | 1 | 2006 | 16 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 1992 | 635 | 0.070 |
Why?
|
| Blood Pressure | 5 | 2015 | 899 | 0.070 |
Why?
|
| Cyclic AMP | 5 | 1985 | 274 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2004 | 171 | 0.070 |
Why?
|
| Absorptiometry, Photon | 1 | 2006 | 99 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2006 | 116 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1991 | 315 | 0.070 |
Why?
|
| Family Health | 1 | 2006 | 162 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2006 | 140 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 31 | 0.060 |
Why?
|
| Glutamates | 1 | 1985 | 89 | 0.060 |
Why?
|
| Estrogens | 1 | 1986 | 201 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 274 | 0.060 |
Why?
|
| In Vitro Techniques | 4 | 2002 | 996 | 0.060 |
Why?
|
| Hyperkalemia | 1 | 1985 | 13 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2005 | 51 | 0.060 |
Why?
|
| Chemical Precipitation | 3 | 2006 | 18 | 0.060 |
Why?
|
| Ricinoleic Acids | 1 | 1984 | 2 | 0.060 |
Why?
|
| Deoxycholic Acid | 1 | 1984 | 10 | 0.060 |
Why?
|
| Taurocholic Acid | 1 | 1984 | 6 | 0.060 |
Why?
|
| Raffinose | 1 | 1984 | 23 | 0.060 |
Why?
|
| Collagen | 1 | 2006 | 293 | 0.060 |
Why?
|
| Oligosaccharides | 1 | 1984 | 24 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1984 | 28 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2006 | 794 | 0.060 |
Why?
|
| Skull | 1 | 1986 | 254 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 91 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 988 | 0.060 |
Why?
|
| Minerals | 1 | 1984 | 22 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1992 | 374 | 0.060 |
Why?
|
| Fetus | 1 | 1985 | 232 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 463 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 2007 | 510 | 0.060 |
Why?
|
| Molecular Weight | 5 | 1991 | 331 | 0.060 |
Why?
|
| Hydrazines | 3 | 1968 | 31 | 0.060 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2023 | 11 | 0.060 |
Why?
|
| Chromatography, DEAE-Cellulose | 3 | 1989 | 20 | 0.060 |
Why?
|
| Glucose | 2 | 2023 | 630 | 0.060 |
Why?
|
| Ethacrynic Acid | 1 | 1983 | 2 | 0.060 |
Why?
|
| Trifluoperazine | 1 | 1983 | 10 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2005 | 202 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 85 | 0.050 |
Why?
|
| Ouabain | 1 | 1983 | 24 | 0.050 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2003 | 27 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 684 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 141 | 0.050 |
Why?
|
| Oxalic Acid | 3 | 1986 | 8 | 0.050 |
Why?
|
| New England | 1 | 2001 | 10 | 0.050 |
Why?
|
| Somatostatin | 1 | 1981 | 53 | 0.050 |
Why?
|
| Buffers | 1 | 2001 | 26 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 1149 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 328 | 0.050 |
Why?
|
| Water | 1 | 2023 | 283 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2001 | 82 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 324 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2003 | 31 | 0.050 |
Why?
|
| Biological Transport, Active | 4 | 1986 | 102 | 0.050 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1980 | 4 | 0.050 |
Why?
|
| Viscosity | 2 | 1991 | 46 | 0.040 |
Why?
|
| Cross Reactions | 2 | 1991 | 109 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1837 | 0.040 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 1999 | 1 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1980 | 61 | 0.040 |
Why?
|
| Zinc Compounds | 1 | 1999 | 6 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1067 | 0.040 |
Why?
|
| Cyanides | 1 | 1999 | 16 | 0.040 |
Why?
|
| Ferrous Compounds | 1 | 1999 | 17 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 681 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1999 | 32 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 1999 | 38 | 0.040 |
Why?
|
| Computers | 2 | 1977 | 112 | 0.040 |
Why?
|
| Radiography | 4 | 2007 | 809 | 0.040 |
Why?
|
| Ammonia | 1 | 2019 | 38 | 0.040 |
Why?
|
| Chlorides | 1 | 1999 | 103 | 0.040 |
Why?
|
| Citrus | 1 | 1999 | 3 | 0.040 |
Why?
|
| Coffee | 1 | 1999 | 10 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 1999 | 42 | 0.040 |
Why?
|
| Tea | 1 | 1999 | 21 | 0.040 |
Why?
|
| Cysteine | 1 | 1999 | 136 | 0.040 |
Why?
|
| Electrophoresis, Disc | 1 | 1998 | 22 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2013 | 3717 | 0.040 |
Why?
|
| Aquaporin 1 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 1998 | 39 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1998 | 27 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1999 | 79 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2006 | 2275 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 1999 | 69 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2011 | 0.040 |
Why?
|
| Community Networks | 1 | 1998 | 30 | 0.040 |
Why?
|
| Chromatography, Gel | 2 | 1991 | 103 | 0.040 |
Why?
|
| Chloride Channels | 1 | 2018 | 42 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 628 | 0.040 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 1998 | 45 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 1998 | 258 | 0.040 |
Why?
|
| Gene Library | 1 | 1998 | 133 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1998 | 33 | 0.040 |
Why?
|
| Titrimetry | 1 | 1997 | 15 | 0.040 |
Why?
|
| Peptides | 2 | 1978 | 646 | 0.040 |
Why?
|
| Alkalosis | 1 | 1977 | 10 | 0.040 |
Why?
|
| Polyribonucleotides | 1 | 1977 | 3 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 1998 | 122 | 0.040 |
Why?
|
| Sulfur | 1 | 1977 | 29 | 0.040 |
Why?
|
| Artifacts | 1 | 1999 | 245 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1998 | 392 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 2 | 1994 | 120 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 191 | 0.040 |
Why?
|
| Christianity | 1 | 1997 | 37 | 0.040 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 20 | 0.040 |
Why?
|
| History, 19th Century | 1 | 1997 | 56 | 0.040 |
Why?
|
| Osteoporosis | 1 | 1998 | 122 | 0.040 |
Why?
|
| Antimetabolites | 1 | 1996 | 24 | 0.040 |
Why?
|
| Nephrologists | 1 | 2016 | 10 | 0.030 |
Why?
|
| Electron Probe Microanalysis | 1 | 1996 | 8 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1940 | 0.030 |
Why?
|
| Urothelium | 2 | 2007 | 71 | 0.030 |
Why?
|
| Transferrins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Drug Costs | 1 | 1996 | 63 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1975 | 0.030 |
Why?
|
| Reminder Systems | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cost of Illness | 1 | 1996 | 147 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1999 | 1714 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 48 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 144 | 0.030 |
Why?
|
| Terminal Care | 1 | 1997 | 137 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 50 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 192 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 305 | 0.030 |
Why?
|
| Hydrochlorothiazide | 1 | 1994 | 41 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 73 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 1994 | 39 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 223 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 356 | 0.030 |
Why?
|
| Epinephrine | 2 | 1985 | 86 | 0.030 |
Why?
|
| Mathematics | 2 | 1988 | 191 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 125 | 0.030 |
Why?
|
| Rats, Mutant Strains | 1 | 1994 | 23 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 283 | 0.030 |
Why?
|
| Radioimmunoassay | 3 | 1982 | 155 | 0.030 |
Why?
|
| Urea | 2 | 2009 | 59 | 0.030 |
Why?
|
| Neoplasms | 1 | 1989 | 3035 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 1986 | 524 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 167 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 595 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 98 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 230 | 0.030 |
Why?
|
| Carbohydrates | 4 | 1985 | 47 | 0.030 |
Why?
|
| Chlorothiazide | 2 | 1982 | 5 | 0.030 |
Why?
|
| Infant | 4 | 2013 | 3147 | 0.030 |
Why?
|
| Malates | 1 | 1992 | 5 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 1988 | 2880 | 0.030 |
Why?
|
| Acetazolamide | 2 | 1985 | 10 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1991 | 60 | 0.020 |
Why?
|
| Natriuresis | 2 | 1986 | 29 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1998 | 590 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 1991 | 117 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1991 | 88 | 0.020 |
Why?
|
| Dihydroxycholecalciferols | 2 | 1981 | 10 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1991 | 177 | 0.020 |
Why?
|
| Hydroxycholecalciferols | 2 | 1981 | 13 | 0.020 |
Why?
|
| Methods | 2 | 1986 | 151 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 1057 | 0.020 |
Why?
|
| Rabbits | 1 | 1991 | 638 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1989 | 29 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1989 | 112 | 0.020 |
Why?
|
| Chronic Disease | 3 | 1985 | 948 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 51 | 0.020 |
Why?
|
| Physicians | 1 | 1977 | 689 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1989 | 25 | 0.020 |
Why?
|
| Adsorption | 1 | 1988 | 54 | 0.020 |
Why?
|
| Antibodies | 1 | 1991 | 353 | 0.020 |
Why?
|
| Cattle | 1 | 1989 | 375 | 0.020 |
Why?
|
| Potassium Citrate | 1 | 2008 | 2 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2008 | 10 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2009 | 78 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1989 | 312 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 443 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1989 | 143 | 0.020 |
Why?
|
| Methylation | 1 | 1968 | 268 | 0.020 |
Why?
|
| Video Recording | 1 | 2008 | 203 | 0.020 |
Why?
|
| Blood | 2 | 1982 | 69 | 0.020 |
Why?
|
| Urography | 1 | 2007 | 45 | 0.020 |
Why?
|
| Urinary Tract Infections | 3 | 1982 | 76 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2007 | 50 | 0.020 |
Why?
|
| Iodohippuric Acid | 1 | 1966 | 2 | 0.020 |
Why?
|
| Radioisotope Renography | 1 | 1966 | 7 | 0.020 |
Why?
|
| Regeneration | 1 | 1967 | 150 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 305 | 0.020 |
Why?
|
| Drinking | 1 | 2006 | 33 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 1986 | 45 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1986 | 120 | 0.020 |
Why?
|
| Atrial Function | 1 | 1986 | 19 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1986 | 39 | 0.020 |
Why?
|
| Microelectrodes | 1 | 1986 | 83 | 0.020 |
Why?
|
| Phase Transition | 1 | 2006 | 18 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2006 | 35 | 0.020 |
Why?
|
| Pregnancy, Animal | 1 | 1986 | 58 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1986 | 135 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2006 | 69 | 0.020 |
Why?
|
| Surface Tension | 1 | 1985 | 8 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1966 | 134 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1986 | 293 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 308 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 1988 | 491 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 1986 | 75 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1985 | 33 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1985 | 38 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 124 | 0.020 |
Why?
|
| Living Donors | 1 | 2009 | 339 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2005 | 29 | 0.020 |
Why?
|
| Sodium Azide | 1 | 1985 | 5 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2006 | 71 | 0.020 |
Why?
|
| Azides | 1 | 1985 | 11 | 0.020 |
Why?
|
| Epithelium | 1 | 1986 | 325 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1967 | 388 | 0.020 |
Why?
|
| Freezing | 1 | 1985 | 32 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1986 | 323 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1989 | 373 | 0.020 |
Why?
|
| Brachytherapy | 1 | 1986 | 121 | 0.020 |
Why?
|
| Systole | 1 | 2005 | 115 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1985 | 77 | 0.020 |
Why?
|
| Electrolytes | 3 | 1982 | 52 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1986 | 127 | 0.020 |
Why?
|
| Diastole | 1 | 2005 | 141 | 0.020 |
Why?
|
| Sheep | 1 | 1985 | 250 | 0.020 |
Why?
|
| Metabolic Diseases | 2 | 1977 | 50 | 0.020 |
Why?
|
| Thiourea | 1 | 1984 | 9 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 1240 | 0.020 |
Why?
|
| Permeability | 1 | 1984 | 137 | 0.010 |
Why?
|
| Osteomalacia | 2 | 1981 | 13 | 0.010 |
Why?
|
| Absorption | 1 | 1984 | 25 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 345 | 0.010 |
Why?
|
| Malabsorption Syndromes | 2 | 1981 | 21 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1984 | 41 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 200 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 234 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 1978 | 2476 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 2335 | 0.010 |
Why?
|
| Extracellular Space | 2 | 1986 | 92 | 0.010 |
Why?
|
| Dogs | 3 | 1968 | 704 | 0.010 |
Why?
|
| Biological Transport | 1 | 1983 | 401 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 948 | 0.010 |
Why?
|
| Software | 1 | 1986 | 665 | 0.010 |
Why?
|
| Meat | 1 | 1981 | 27 | 0.010 |
Why?
|
| Rickets | 1 | 1981 | 5 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 620 | 0.010 |
Why?
|
| Calcifediol | 1 | 1981 | 20 | 0.010 |
Why?
|
| Hypoparathyroidism | 1 | 1981 | 24 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2612 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 688 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1980 | 15 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1981 | 72 | 0.010 |
Why?
|
| Osteitis Fibrosa Cystica | 1 | 1980 | 4 | 0.010 |
Why?
|
| Viomycin | 1 | 1980 | 1 | 0.010 |
Why?
|
| Cellulose | 1 | 1980 | 55 | 0.010 |
Why?
|
| Oxygen | 1 | 1985 | 742 | 0.010 |
Why?
|
| Placebos | 1 | 1980 | 214 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1980 | 58 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1978 | 25 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 270 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 1239 | 0.010 |
Why?
|
| Hypertrophy | 2 | 1968 | 67 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1977 | 50 | 0.010 |
Why?
|
| Aldosterone | 1 | 1977 | 56 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 1977 | 96 | 0.010 |
Why?
|
| Cystoscopy | 1 | 1977 | 39 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1978 | 58 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 1977 | 66 | 0.010 |
Why?
|
| Guanethidine | 1 | 1977 | 3 | 0.010 |
Why?
|
| Methyldopa | 1 | 1977 | 3 | 0.010 |
Why?
|
| Syndrome | 1 | 1978 | 449 | 0.010 |
Why?
|
| Dyspnea | 1 | 1977 | 75 | 0.010 |
Why?
|
| Hydralazine | 1 | 1977 | 19 | 0.010 |
Why?
|
| Constriction | 1 | 1976 | 27 | 0.010 |
Why?
|
| Dehydration | 1 | 1976 | 20 | 0.010 |
Why?
|
| Pedigree | 1 | 1979 | 969 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1978 | 117 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1981 | 1296 | 0.010 |
Why?
|
| Palliative Care | 1 | 1978 | 263 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1978 | 995 | 0.010 |
Why?
|
| Vomiting | 1 | 1977 | 194 | 0.010 |
Why?
|
| Liver | 1 | 1981 | 1205 | 0.010 |
Why?
|
| Diphosphates | 1 | 1975 | 18 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1976 | 171 | 0.010 |
Why?
|
| Methionine | 1 | 1975 | 65 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1978 | 426 | 0.010 |
Why?
|
| Aorta | 1 | 1976 | 288 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1977 | 783 | 0.010 |
Why?
|
| Chondrocalcinosis | 1 | 1974 | 8 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 1974 | 74 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1978 | 975 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1980 | 758 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1977 | 1591 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1973 | 12 | 0.010 |
Why?
|
| Uremia | 1 | 1973 | 14 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 1987 | 1710 | 0.010 |
Why?
|
| Renin | 1 | 1973 | 67 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1974 | 160 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1973 | 93 | 0.010 |
Why?
|
| Hospitalization | 1 | 1977 | 876 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1968 | 18 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1989 | 108 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 1968 | 36 | 0.000 |
Why?
|
| Tritium | 1 | 1967 | 133 | 0.000 |
Why?
|
| Leucine | 1 | 1967 | 60 | 0.000 |
Why?
|
| Colic | 1 | 1987 | 7 | 0.000 |
Why?
|
| Dinitrophenols | 1 | 1967 | 7 | 0.000 |
Why?
|
| Thiamine | 1 | 1967 | 8 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1978 | 2411 | 0.000 |
Why?
|
| Radiation Protection | 1 | 1986 | 26 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1967 | 145 | 0.000 |
Why?
|
| Kidneys, Artificial | 1 | 1966 | 4 | 0.000 |
Why?
|
| Radiometry | 1 | 1966 | 56 | 0.000 |
Why?
|
| Catheters, Indwelling | 1 | 1986 | 113 | 0.000 |
Why?
|
| Surgical Mesh | 1 | 1986 | 122 | 0.000 |
Why?
|
| Body Weight | 1 | 1986 | 452 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1986 | 576 | 0.000 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1981 | 44 | 0.000 |
Why?
|
| Arteries | 1 | 1982 | 180 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1982 | 682 | 0.000 |
Why?
|
| Thermodynamics | 1 | 1981 | 311 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1986 | 1363 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1977 | 69 | 0.000 |
Why?
|
| Parity | 1 | 1977 | 96 | 0.000 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1977 | 109 | 0.000 |
Why?
|
| Hemochromatosis | 1 | 1974 | 11 | 0.000 |
Why?
|
| Gout | 1 | 1974 | 75 | 0.000 |
Why?
|
| Iron | 1 | 1974 | 168 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1974 | 170 | 0.000 |
Why?
|
| Salicylates | 1 | 1966 | 25 | 0.000 |
Why?
|